Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions

Liver Diseases Clinical Trial

Official title:

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions: Observational Case Control Study in Upper Egypt

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03172650
• Other study ID #: NAFLD
• Status: Recruiting
• Phase: N/A
• First received: May 30, 2017
• Last updated: August 13, 2017
• Start date: July 1, 2017
• Est. completion date: September 2018

Study information

• Verified date: August 2017
• Source: Assiut University
• Contact: Mahmoud Ali, MBBCh
• Phone: 00201144287363
• Email: ans1111eg[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver disease including viral, drug-induced, or autoimmune. Non-alcoholic fatty liver disease is a hepatic manifestation of metabolic syndrome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria:

• All non alcoholic fatty liver disease patients evidenced by abdominal ultrasound.

• Urine analysis whether normal or renal sedimentation.

Exclusion criteria:

1. Alcoholic fatty liver patients.

2. patients known to have diabetes mellitus.

3. patients with other causes of liver disease as viral hepatitis, drug induced,or autoimmune.

4. patients known to have kidney disease.

5. Hypertension.

6. Hyperuricemia.

7. Impaired urea and creatinine patients.

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease

Intervention

Diagnostic Test:
• glomerular filtration rate
collection of blood sample 5 milliliter for calculation of glomerular filtration rate

Locations

Country	Name	City	State
Egypt	Ahmed Abbas	Assiut	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of patients with abnormal laboratory glomerular filtration rate	decreased glomerular filtration rate <60 mL/minute will be considered abnormal	1 day